Issue Archive

In this issue of Blood, Chou et al¹  and Pulikkan et al²  reveal that the (8;21)(q22;q22) translocation product AML1-ETO (RUNX1-RUNX1T1) leads to enhanced JAK/STAT signaling downstream of myeloproliferative leukemia (MPL) virus, which in turn contributes to increased survival of tumor cells. Hijacking of the JAK/STAT pathway through up-regulation of wild-type MPL is a new paradigm for hematologic malignancies.

In this issue of Blood, Josephson et al report age group analyses of patients enrolled in the prophylactic platelet dose trial (PLADO) that evaluated the relationship between platelet dose per transfusion and bleeding in hospitalized patients with treatment-induced hypoproliferative thrombocytopenia.¹ 

In this issue of Blood, Shibeko et al have used a variety of experimental studies and mathematical models to investigate the mechanism of action of high-dose factor VIIa as a bypassing agent in hemophilia.¹